Xvivo Perfusion AB (publ) (XVIPF)
OTCMKTS · Delayed Price · Currency is USD
20.54
0.00 (0.00%)
Aug 6, 2025, 8:00 PM EDT
Xvivo Perfusion AB Revenue
Xvivo Perfusion AB had revenue of 178.30M SEK in the quarter ending June 30, 2025, a decrease of -15.24%. This brings the company's revenue in the last twelve months to 822.93M, up 17.78% year-over-year. In the year 2024, Xvivo Perfusion AB had annual revenue of 822.42M with 37.63% growth.
Revenue (ttm)
822.93M SEK
Revenue Growth
+17.78%
P/S Ratio
7.18
Revenue / Employee
4.33M SEK
Employees
190
Market Cap
621.52M USD
Revenue Chart
* This company reports financials in SEK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 822.42M | 224.87M | 37.63% |
Dec 31, 2023 | 597.54M | 182.25M | 43.88% |
Dec 31, 2022 | 415.29M | 156.91M | 60.73% |
Dec 31, 2021 | 258.39M | 78.53M | 43.66% |
Dec 31, 2020 | 179.86M | -40.98M | -18.55% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |
Xvivo Perfusion AB News
- 4 weeks ago - Xvivo Perfusion AB (XVIPF) Q2 2025 Earnings Call Highlights: Navigating Challenges and Seizing ... - GuruFocus
- 4 weeks ago - Q2 2025 Xvivo Perfusion AB Earnings Call Transcript - GuruFocus